KR20100028554A - 17β-시아노-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약 - Google Patents

17β-시아노-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약 Download PDF

Info

Publication number
KR20100028554A
KR20100028554A KR1020097025930A KR20097025930A KR20100028554A KR 20100028554 A KR20100028554 A KR 20100028554A KR 1020097025930 A KR1020097025930 A KR 1020097025930A KR 20097025930 A KR20097025930 A KR 20097025930A KR 20100028554 A KR20100028554 A KR 20100028554A
Authority
KR
South Korea
Prior art keywords
cyano
androst
methylene
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097025930A
Other languages
English (en)
Korean (ko)
Inventor
요아킴 쿤케
얀 휘브너
롤프 볼만
토마스 프렌첼
울리히 클라르
프레더리크 멩게스
스펜 링
스테펜 보르덴
한스-페터 문
카챠 프렐레
Original Assignee
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 쉐링 파마 악티엔게젤샤프트
Publication of KR20100028554A publication Critical patent/KR20100028554A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097025930A 2007-06-12 2008-06-04 17β-시아노-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약 Withdrawn KR20100028554A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007027637.2 2007-06-12
DE102007027637A DE102007027637A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
KR20100028554A true KR20100028554A (ko) 2010-03-12

Family

ID=39986163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097025930A Withdrawn KR20100028554A (ko) 2007-06-12 2008-06-04 17β-시아노-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약

Country Status (20)

Country Link
US (1) US8207150B2 (enExample)
EP (1) EP2170925B1 (enExample)
JP (1) JP2010529153A (enExample)
KR (1) KR20100028554A (enExample)
CN (1) CN101679478A (enExample)
AR (1) AR066971A1 (enExample)
AU (1) AU2008261278A1 (enExample)
BR (1) BRPI0813937A2 (enExample)
CA (1) CA2690959A1 (enExample)
DE (1) DE102007027637A1 (enExample)
ES (1) ES2397996T3 (enExample)
IL (1) IL202359A0 (enExample)
MX (1) MX2009013629A (enExample)
PA (1) PA8784401A1 (enExample)
PE (1) PE20090822A1 (enExample)
RU (1) RU2010100331A (enExample)
TW (1) TW200909444A (enExample)
UY (1) UY31146A1 (enExample)
WO (1) WO2008151746A2 (enExample)
ZA (1) ZA201000187B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN104530165A (zh) * 2014-12-10 2015-04-22 浙江仙琚制药股份有限公司 制备4,9-双烯物的方法
CN105085596A (zh) * 2015-08-18 2015-11-25 湖北竹溪人福药业有限责任公司 一种羧酸黄体酮的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (enExample) 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
DE2456068A1 (de) 1974-11-23 1976-08-12 Schering Ag Verfahren zur herstellung von oestren3,17-dion-derivaten
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DD281393A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen
DD281394A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
WO2008151746A3 (de) 2009-03-12
US20090048217A1 (en) 2009-02-19
PE20090822A1 (es) 2009-07-25
EP2170925B1 (de) 2012-10-24
TW200909444A (en) 2009-03-01
WO2008151746A2 (de) 2008-12-18
RU2010100331A (ru) 2011-07-20
EP2170925A2 (de) 2010-04-07
ZA201000187B (en) 2011-03-30
MX2009013629A (es) 2010-01-20
US8207150B2 (en) 2012-06-26
ES2397996T3 (es) 2013-03-13
BRPI0813937A2 (pt) 2014-12-30
DE102007027637A1 (de) 2008-12-18
AU2008261278A1 (en) 2008-12-18
UY31146A1 (es) 2009-01-30
CN101679478A (zh) 2010-03-24
CA2690959A1 (en) 2008-12-18
PA8784401A1 (es) 2009-01-23
AR066971A1 (es) 2009-09-23
IL202359A0 (en) 2010-06-30
JP2010529153A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
KR20100017780A (ko) 17베타-시아노-18ａ-호모-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약
US7846917B2 (en) 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same
KR20070093443A (ko) 18-메틸-19-노르-17-프레근-4-엔-21,17-카르보락톤 및 이를포함하는 제약 제제
US8207150B2 (en) 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative
AU2008266526A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
CN101910192B (zh) 具有15α,16α-亚甲基和饱和的17,17-螺内酯环的19-去甲甾类衍生物、其应用以及包含这些衍生物的药物
KR20100037596A (ko) 17β-시아노-19-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약
JP5600068B2 (ja) １７−ヒドロキシ−１９−ノル−２１−カルボン酸−ステロイドγ−ラクトン誘導体、それらの使用および前記誘導体を含有する医療製品
KR20100110348A (ko) １５,１６-메틸렌-１７-(１'-프로페닐)-１７,３'-옥시도에스트라-４-엔-３-온 유도체, 그의 용도, 및 상기 유도체를 함유하는 약제
KR20100094999A (ko) １５,１６-메틸렌-１７-히드록시-１９-노르-２１-카르복실산 γ-락톤 유도체, 그의 용도 및 상기 유도체를 함유하는 의약
JP5600069B2 (ja) １７−（１’−プロペニル）−１７−３’−オキシドエストラ−４−エン−３−オン誘導体、その使用及び当該誘導体を含む医薬品
HK1141535A (en) 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
HK1141537A (en) 17β-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
HK1141536A (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
HK1151801B (en) 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID γ-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE
HK1151532B (en) 19-NOR-STEROID DERIVATIVES WITH A 15α,16α-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES
TW201029656A (en) Use of 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for parenteral administration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid